News

Scientists have developed a new approach that is less complex and does not require extracting the genetic RNA material of the virus.

The Academy has stepped up to speak out against the use of untested biosimilars in the eyes of patients amid a disruption in the drug supply chain.

Aequus Pharmaceuticals, reVision Therapeutics announced this week that they will collaborate to develop a therapy for Stargardt disease.

Oxurion is currently recruiting patients for the Phase 2 clinical study of THR-687 in DME.

The company shared data from its two-year Phase III KITE trial and the one-year phase III KINGFISHER trial.

Tool for quantifying measures may predict outcomes for patients.

Substantial weight loss can help patients’ eye health, study results show.

The Research to Prevent Blindness (RPB), the Association of University Professors of Ophthalmology (AUPO) and an anonymous donor have recognized Donald Zack, MD, PhD, for ground-breaking contributions to the field of vision research.

According to Oculus, its Myopia Master saves space and can be mounted on a workstation or an ophthalmic table. The software is operated directly via an inbuilt display.

The company is evaluating topical cyclosporine to treat the signs and symptoms of dry eye disease.

According to the Refractive Surgery Council, patients continue to have a high level of interest in laser vision correction procedures.

Taking control of a practice’s future with investment, creative thinking

pVerify's Vision Benefits API allows front-office staff to handle vision eligibility verifications seamlessly in their own EHR.

Most patients with allergic disorder are children, adolescents, or young adults.

Llama nanobodies may be key to beating COVID-19 variants.

Heru Inc., announced Thursday that it has partnered with Vision Source on the commercial availability launch of re:Vive, a wearable diagnostics and visual field application.

Outlook Therapeutics has reported positive efficacy and safety data from Phase 3 NORSE TWO trial of bevacizumab-vikg.

The organization hopes to help 1 billion people worldwide, committing the international community to improve vision for 1.1 billion people living with preventable vision loss by 2030.

Perhaps the most important consideration is understanding the neuromuscular pathway that retracts and protracts the eyelid.

Use of a drug to correct the eyelid position could eliminate the complications associated with surgery.

Investigators uncovered evidence that CaMKII could prove to be a desirable therapeutic target for vision preservation in conditions that damage the axons and somas of retinal ganglion cells.

A team of investigators used corneal confocal microscopy to identify corneal nerve damage in cases of long COVID.

Jag Dosanjh, senior vice president of U.S. Eye Care, Allergan, an AbbVie company, offers a preview of the company's latest innovations, developments, and what attendees can look forward to at ASCRS 2021.

This announcement was made at the 2021 ASCRS annual meeting.

A new report has found that glaucoma specialists’ procedure of choice has changed as a result of the COVID-19 pandemic.

AAO, Surgical Care Coalition teaming up to ensure the final version of the rule is fair to ophthalmologists and surgeons as one company is expressing its disappointment in the proposal.

Nanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells.